PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women

Launched by INTERNATIONAL AGENCY FOR RESEARCH ON CANCER · May 5, 2017

Keywords

ClinConnect Summary

The PRECAMA study is focused on understanding breast cancer in young women aged 20 to 45 in Latin America. Breast cancer is a serious concern in this region, as women are often diagnosed at a younger age and at more advanced stages compared to women in other parts of the world. This study aims to gather information about the different types of breast cancer that affect premenopausal women, as well as the factors that may contribute to these cases. By collecting clinical, biological, and personal information, the researchers hope to improve prevention strategies and treatment options for breast cancer in Latin America.

To be eligible for this study, participants must be women between the ages of 20 and 45, must have been diagnosed with breast cancer within the last three years, and must have been living in the study area for at least three years. Women who are currently undergoing cancer treatment or have certain medical conditions may not qualify. Participants can expect to provide information about their health and lifestyle, and they may also be asked to provide biological samples for analysis. This study is important as it seeks to enhance knowledge about breast cancer in young women in Latin America, which can ultimately lead to better health outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • woman between 20 and 45 years old
• • woman less than 3 years older or younger than the case
• • living in the area that the study is taking place during the past 3 years
• • woman menstruated at least once in the past 12 months
• • woman diagnosed with a primary breast cancer by histopathological examination (only for cases)
• Exclusion Criteria:
• • woman receiving tumor treatment, such as radiotherapy, chemotherapy or anti-estrogens (for example, tamoxifen) (except treatment for non-melanoma skin cancers)
• • woman taking (or has previously taken) any of the following medications in the past 6 months: tamoxifen, Evista (raloxifene), Fareston (toremifene), Aromasin (exemestane), Femara (letrozole), Arimidez (anastrozole) or Megace (megestrol)
• • woman suffering from chronic kidney failure
• • woman having a pathology that will hinder adequate communication
• • woman who is pregnant or nursing
• • woman who has been previously diagnosed with a cancer(except for non-melanoma skin cancers)
• • any other reason to exclude